- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 29.01. | Bayer broadcasts patient stories with Tony Romo calling plays in Nubeqa drive | ||
| 28.01. | The new rules of biopharma M&A: 4 trends driving dealmaking this year | ||
| 28.01. | Advocacy group files FOIA lawsuit to gain further clarity on Trump administration's MFN pricing deals | ||
| 28.01. | Halozyme catches M&A wave to snap up Surf Bio in delivery tech deal worth up to $400M | ||
| 28.01. | Antheia seals 2nd series C funding close, hitting more than $175M in a year | ||
| 28.01. | Teva, after third straight year of growth, expects downturn in 2026 | ||
| 28.01. | Ro serves up Super Bowl GLP-1 campaign starring Serena Williams | ||
| 28.01. | Cellares' series D round draws $257M as cell therapy contractor takes operations global | ||
| 27.01. | China regulators suspend sale of Sun Pharma's dementia med after site inspection | ||
| 27.01. | EU looks to knock out pharmaceutical export tariffs in sweeping free trade pact with India | ||
| 27.01. | Servier delivers 16% revenue jump, firming up €10B ambition by 2030 | ||
| 27.01. | Pfizer retains top spot in vaccine rankings as Sanofi's slide sparks 'code red' call | ||
| 27.01. | Siegfried extends M&A streak, gaining 3 sites from SK Capital and advancing US onshoring aims | ||
| 26.01. | Catalent moves to wind down operations at EU cell therapy manufacturing hub | ||
| 26.01. | New rules, higher stakes: Biopharma plays the long game in 2026 | ||
| 26.01. | Arcutis, Kowa part ways on US marketing partnership for Zoryve | ||
| 26.01. | Daiichi Sankyo navigates complexity of success as Enhertu, Datroway push for market dominance | ||
| 26.01. | Responding to tougher FDA standards, Recipharm debuts new facility for beta-lactam drugs | ||
| 23.01. | Anti-vaccine sentiment pushes Moderna away from new late-stage infectious disease trials | ||
| 23.01. | ST Pharm inks $56M deal to produce API for a US biotech | ||
| 23.01. | Lilly battles weight stigma in short film centering obesity conversation on health, not appearance | ||
| 23.01. | RFK Jr.'s new ACIP chair stresses 'individual autonomy,' questions polio shot guidance on podcast | ||
| 23.01. | Novo's Wegovy pill launch wows with strong early uptake: analysts | ||
| 23.01. | Bausch Health's $2B pursuit of Xifaxan successor hits wall with phase 3 failure | ||
| 23.01. | Ocular drafts Eylea launch architect to lead attack on Regeneron's blockbuster |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.